TerraForm Power Reports 2015 Financial Results and Files Form 10-K
Dec 05, 2016 12:45 pm UTC| Business
BETHESDA, Md., Dec. 05, 2016 -- TerraForm Power, Inc. (Nasdaq:TERP) (“TerraForm Power”), a global owner and operator of clean energy power plants, today reported 2015 financial results and filed its Form 10-K for 2015...
NCL Corporation Ltd. Announces Cash Tender Offer for its 5.25% Senior Notes Due 2019
Dec 05, 2016 12:37 pm UTC| Business
MIAMI, Dec. 05, 2016 -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NASDAQ:NCLH) (“NCLH”), announced today that it has commenced a cash tender offer (the “Tender Offer”) to...
NCL Corporation Ltd. Announces Proposed $700,000,000 Debt Offering
Dec 05, 2016 12:34 pm UTC| Business
MIAMI, Dec. 05, 2016 -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NASDAQ:NCLH) (“NCLH”), announced today that it is proposing to sell $700.0 million aggregate principal amount...
Dec 05, 2016 12:30 pm UTC| Business
SAN DIEGO, Dec. 05, 2016 -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced the presentation yesterday of two preclinical data sets, one oral presentation and one poster presentation, for TGR-1202, the Company’s...
KaloBios Highlights Priority Milestones in Letter to Stakeholders
Dec 05, 2016 12:30 pm UTC| Business
BRISBANE, Calif., Dec. 05, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD,...
Caladrius Biosciences to Present at Upcoming December Conferences
Dec 05, 2016 12:30 pm UTC| Business
BASKING RIDGE, N.J., Dec. 05, 2016 -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading...
Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
Dec 05, 2016 12:30 pm UTC| Business
PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY‑ESO SPEAR™...